Comparative Pharmacology
Head-to-head clinical analysis: ESTRADURIN versus ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADURIN versus ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL.
ESTRADURIN vs ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen receptor agonist; estradiol valerate is a prodrug that releases estradiol, which binds to and activates estrogen receptors (ERα and ERβ), modulating gene transcription and cellular signaling.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estradurin (polyestradiol phosphate) is administered intramuscularly at a dose of 40 mg every 2 to 4 weeks for the treatment of prostate cancer.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Terminal half-life: 5-7 days (estradiol valerate); prolonged due to esterification and slow release from adipose tissue. Clinical context: steady-state achieved after 2-3 months with monthly dosing.
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Renal: 50-80% as glucuronide and sulfate conjugates, biliary/fecal: 20-30% as conjugates
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Category C
Category D/X
Estrogen
Estrogen